journal
MENU ▼
Read by QxMD icon Read
search

Journal of Viral Hepatitis

journal
https://www.readbyqxmd.com/read/28845882/rare-clinically-significant-hepatic-events-and-hepatitis-b-reactivation-occur-more-frequently-following-rather-than-during-direct-acting-antiviral-therapy-for-chronic-hepatitis-c-data-from-a-national-us-cohort
#1
Marina Serper, Kimberly A Forde, David E Kaplan
Recently, cases of hepatitis B virus reactivation (HBVr) with direct acting antiviral therapy (DAAs) for HCV have been reported. However, few data exist from large, Western cohorts. The study objectives were to evaluate the incidence of alanine aminotransferase (ALT) flares, clinically significant hepatic events, and HBVr among a national cohort of US veterans with prior exposure to HBV (anti-HBc+) treated with DAAs. We used a national administrative database to identify patients treated with DAAs from January 2014 through November 2016 and obtained clinical and demographic as well as HBV and HCV treatment data...
August 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28834100/the-epidemiology-of-hepatitis-b-virus-infection-in-women-of-reproductive-age-in-highly-endemic-areas-in-china
#2
H Zheng, F Q Cui, F Z Wang, L F Huang, X P Shao, J F Du, J Li, Y Zhou, H Z Zheng, J T Zhuo, X X Zeng, G M Zhang, N Miao, X J Sun, X F Liang, H M Luo
We describe the epidemiology of hepatitis B virus (HBV) infection among women of reproductive age residing in areas of China that are highly endemic for chronic HBV, and provide evidence useful for decision-makers to guide strategies for preventing mother-to-child transmission of HBV, and assess the impact of perinatal transmission PMTCT by projecting HBsAg prevalence trends without interventions. We conducted a cross-sectional HBV serological survey of women, 15-49 years of age, residing in Fujian, Guangdong, Guangxi and Hainan provinces...
August 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28833938/efficacy-and-safety-results-of-patients-with-hcv-genotype-2-or-3-infection-treated-with-ombitasvir-paritaprevir-ritonavir-and-sofosbuvir-with-or-without-ribavirin-quartz-ii-iii
#3
Stephen D Shafran, David Shaw, Mariem Charafeddine, Kosh Agarwal, Graham R Foster, Manal Abunimeh, Tami Pilot-Matias, Rajvineeth K Pothacamury, Bo Fu, Eric Cohen, Daniel E Cohen, Edward Gane
The efficacy and safety of an investigational combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus sofosbuvir (SOF) ± ribavirin (RBV) in patients with HCV genotype 2 or 3 infection with or without cirrhosis was evaluated. Patients with HCV genotype 3 infection without cirrhosis were randomized to receive OBV/PTV/r + SOF ± RBV for 12 weeks; OBV/PTV/r + SOF + RBV was administered to genotype 3-infected patients with cirrhosis for 12 weeks and to genotype 2-infected patients without cirrhosis for either 6 or 8 weeks...
August 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28833932/nonstructural-protein-5a-ns5a-resistance-profile-in-patients-with-chronic-hepatitis-c-treated-with-ledipasvir-containing-regimens-without-sofosbuvir
#4
Kathryn M Kitrinos, Amoreena C Corsa, Angela Worth, Charlotte Hedskog, Diana Brainard, Michael D Miller, Hongmei Mo
The study aimed to evaluate the effects of baseline hepatitis C virus (HCV) NS5A resistance-associated substitutions (RASs) on sustained virologic response to ledipasvir (LDV)-containing regimens in the absence of sofosbuvir (SOF) in patients with HCV genotype (GT) 1 infection across 6 phase 2 clinical studies. We analyzed data from 1103 patients who received either LDV+vedroprevir (NS3 PI)+tegobuvir (NS5B inhibitor)±ribavirin or LDV+ribavirin+pegylated interferon. Population sequencing of HCV NS5A was performed at baseline and at virologic failure from patient plasma samples...
August 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28815822/hepatitis-c-virus-related-complications-are-increasing-in-women-veterans-a-national-cohort-study
#5
J R Kramer, H B El-Serag, T J Taylor, D L White, S M Asch, S M Frayne, Y Cao, D L Smith, F Kanwal
There are gender-specific variations in the epidemiology and clinical course of hepatitis C virus (HCV) infection. However, few long-term longitudinal studies have examined trends in the incidence and prevalence of serious liver complications among women compared with men with HCV infection. We used the Veterans Administration Corporate Data Warehouse to identify all veterans with positive HCV viraemia from January 2000 to December 2013. We calculated gender-specific annual incidence and prevalence rates of cirrhosis, decompensated cirrhosis and hepatocellular cancer (HCC) adjusting for age, diabetes, HIV and alcohol use...
August 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28787102/a-different-perspective-on-sofosbuvir-ledipasvir-treatment-of-patients-with-hcv-genotype-1b-cirrhosis-the-ital-c-network-study
#6
Michele Barone, Andrea Iannone, Endrit Shahini, Antonio Massimo Ippolito, Giuseppina Brancaccio, Filomena Morisco, Michele Milella, Vincenzo Messina, Antonina Smedile, Fabio Conti, Pietro Gatti, Teresa Santantonio, Paolo Tundo, Gianfranco Lauletta, Nicola Napoli, Chiara Masetti, Antonio Patrizio Termite, Ruggiero Francavilla, Alfredo Di Leo, Francesco Pesce, Angelo Andriulli
The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype 1b-infected patients with cirrhosis is still under debate. Our primary endpoint was to compare the sustained virological response at post-treatment week 12 (SVR12) of sofosbuvir-ledipasvir in combination with ribavirin for 12 weeks, and sofosbuvir-ledipasvir alone for 24 weeks. This was a prospective observational study that enrolled 424 (195 naive, 229 experienced; 164 treated for 12 weeks with Ribavirin and 260 with sofosbuvir-ledipasvir alone for 24 weeks) consecutive HCV genotype 1b-infected patients with cirrhosis...
August 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28783247/bacterial-translocation-and-clinical-progression-of-hcv-related-cirrhosis-in-hiv-infected-patients
#7
N Merchante, T Aldámiz-Echevarría, M García-Álvarez, A Rivero-Juárez, J Macías, P Miralles, M A Jiménez-Sousa, M Mancebo, L Pérez-Latorre, D Pineda-Tenor, J Berenguer, S Resino, J A Pineda
The aim of the study was to evaluate whether bacterial translocation (BT) predicts the clinical outcome in HIV/HCV-coinfected patients with compensated cirrhosis. A cohort of 282 HIV/HCV-coinfected patients with cirrhosis and no previous liver decompensation (LD) was recruited. Serum levels of the DNA sequences encoding the well-conserved 16S rRNA subunit (16S rDNA), the lipopolysaccharide (LPS) and soluble CD14 (sCD14) at diagnosis of cirrhosis were measured. Primary endpoint was the emergence of the first LD and/or death of any cause...
August 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28783205/successful-treatment-of-chronic-hepatitis-c-with-ground-ledipasvir-sofosbuvir-in-a-patient-with-crohn-s-disease-and-short-bowel-syndrome
#8
Johann von Felden, Christoph Scheurich, Jin Yamamura, Diana M Brainard, Erik Mogalian, Ansgar W Lohse, Julian Schulze-Zur-Wiesch
We read the comprehensive review by Gitto et al. entitled 'NS5A inhibitors for the treatment of hepatitis C infection' (CHC) with great interest (1). Indeed, the development of direct acting antivirals (DAAs) now enables successful treatment of formerly difficult-to-treat patient populations (e.g. cirrhosis or chronic kidney disease). However, little is known about the use of DAAs in patients with short bowel syndrome, e.g. following inflammatory bowel disease (IBD), because these patients are yet excluded from clinical trials (2)...
August 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28772350/claudin-1-mir-122-and-apolipoprotein-e-transductions-improve-the-permissivity-of-snu-182-snu-398-and-snu-449-hepatoma-cells-to-hepatitis-c-virus
#9
C Fournier, T W Hoffmann, V Morel, V Descamps, J Dubuisson, E Brochot, C Francois, G Duverlie, S Castelain, F Helle
Hepatitis C virus (HCV) is a human hepatotropic virus, but many hepatoma cell lines are not permissive to this virus. In a previous study, we observed that SNU-182, SNU-398 and SNU-449 hepatoma cell lines were nonpermissive to HCV. To understand the nonpermissivity, we evaluated the ability of each cell line to support the different steps of HCV life cycle (entry, replication and production of infectious particles). Using retroviral pseudoparticles pseudotyped with HCV envelope proteins and recombinant HCV produced in cell culture, we observed that low level or absence of claudin-1 (CLDN1) expression limited the viral entry process in SNU-182 and SNU-398 cells, respectively...
August 3, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28772340/inverse-relationship-between-hepatic-steatosis-and-hepatitis-b-viremia-results-of-a-large-case-control-study
#10
Rex Wh Hui, Wai-Kay Seto, Ka-Shing Cheung, Lung-Yi Mak, Kevin Sh Liu, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai, Man-Fung Yuen
The potential interaction between chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD), two of the most prevalent liver diseases worldwide, has not been well-defined. We performed liver stiffness (LS) and controlled attenuation parameter (CAP) measurements using transient elastography in 1202 CHB patients. Of these, 601 steatotic patients were matched with non-steatotic controls in a 1:1 ratio by age, gender, nucleoside analogue treatment status, and treatment duration. Severe fibrosis was defined according to EASL-ALEH criteria, and steatosis defined as CAP ≥222 dB m(-1) ...
August 3, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28750141/hepatocellular-carcinoma-in-patients-with-chronic-hepatitis-c-and-cirrhosis-in-denmark-a-nationwide-cohort-study
#11
Sofie Hallager, Steen Ladelund, Mette S Kjaer, Lone G Madsen, Erika Belard, Alex Lund Laursen, Jan Gerstoft, Birgit T Røge, Karin E Grønbaek, Henrik B Krarup, Peer B Christensen, Nina Weis
Cirrhosis in patients with chronic hepatitis C increases the risk of hepatocellular carcinoma (HCC) and surveillance with ultrasound (US) and alpha-fetoprotein (AFP) is recommended. This study aimed to estimate changes in the HCC incidence rate (IR) over time, HCC stage and prognosis, and AFP and US performed in patients with hepatitis C and cirrhosis. Eligible patients were identified in the Danish Database for Hepatitis B and C and data from national health registries and patient charts were obtained. Tumor stage was based on Barcelona-Clinic Liver Cancer stage, TNM classification and size and number of lesions combined into stage 0 - 3...
July 27, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28719060/drug-use-and-phylogenetic-clustering-of-hepatitis-c-virus-infection-among-people-who-use-drugs-in-vancouver-canada-a-latent-class-analysis-approach
#12
Brendan Jacka, Bethany Bray, Tanya L Applegate, Brandon Dl Marshall, Viviane Dias Lima, Kanna Hayashi, Kora DeBeck, Jayna Raghwani, P Richard Harrigan, Mel Krajden, Julio Montaner, Jason Grebely
BACKGROUND: This study estimated latent classes (i.e., unobserved subgroups in a population) of people who use drugs in Vancouver, Canada and examined how these classes relate to phylogenetic clustering of hepatitis C virus (HCV) infection. METHODS: HCV antibody positive people who use drugs from two cohorts in Vancouver, Canada (1996-2012) with a Core-E2 sequence were included. Time-stamped phylogenetic trees were inferred and phylogenetic clustering was determined by time to most common recent ancestor...
July 18, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28719029/directly-observed-therapy-of-sofosbuvir-ribavirin-peginterferon-with-minimal-monitoring-for-the-treatment-of-chronic-hepatitis-c-in-people-with-a-history-of-drug-use-in-chennai-india-c-dot
#13
S S Solomon, M S Sulkowski, P Amrose, A K Srikrishnan, A M McFall, B Ramasamy, M S Kumar, S Anand, D L Thomas, S H Mehta
We assessed the feasibility of field-based directly observed therapy (DOT) with minimal monitoring to deliver HCV treatment to people with a history of drug use in Chennai, India. Fifty participants were randomized 1:1 to sofosbuvir+peginterferon alfa 2a+ribavirin (SOF+PR) for 12 weeks (Arm 1) vs sofosbuvir+ribavirin (SOF+R) for 24 weeks (Arm 2). SOF+R was delivered daily at participant chosen venues and weekly peginterferon injections at the study clinic. HCV RNA testing was performed to confirm active HCV infection and sustained virologic response 12 weeks after treatment completion (SVR12)...
July 18, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28710798/can-quantitative-hepatitis-b-surface-antigen-levels-predict-the-severity-of-liver-disease-in-genotype-e-patients
#14
Gayatri Chakrabarty, Matthew Bruce, Mary Horner, Bo Wang, Kosh Agarwal, Ivana Carey
The utility of quantitative Hepatitis B surface antigen (qHBsAg) level as a marker of chronic hepatitis B (CHB)-related liver damage is not fully delineated, but is becoming increasingly relevant. Quantitative HBsAg levels are linked with progression of liver disease in HBeAg-negative genotype B and C patients, but it is not clear whether this is consistent across all HBV genotypes. In this single-centre, cross-sectional observational study, we evaluated whether qHBsAg levels can predict the severity of liver disease in genotype E patients...
July 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28703895/hbv-reactivation-in-patients-with-hcv-hbv-cirrhosis-on-treatment-with-direct-acting-antivirals
#15
Vincenza Calvaruso, Donatella Ferraro, Anna Licata, Maria Grazia Bavetta, Salvatore Petta, Fabrizio Bronte, Giuseppina Colomba, Antonio Craxì, Vito Di Marco
Anecdotal reports suggest that patients with chronic HCV hepatitis and overt or occult HBV co-infection may reactivate HBV when HCV is suppressed or cleared by DAAs. We assessed the prevalence of overt or previous HBV co-infection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up...
July 13, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28692182/gsk2878175-a-pan-genotypic-non-nucleoside-ns5b-polymerase-inhibitor-in-healthy-and-treatment-na%C3%A3-ve-chronic-hepatitis-c-subjects
#16
Stephen D Gardner, Joseph Kim, Sharon Baptiste-Brown, Vincent Lopez, Robert Hamatake, Jianjun Gan, Stephen Edwards, Lucinda Elko-Simms, Etienne F Dumont, Martin Leivers, Zhi Hong, Melanie T Paff
GSK2878175 is a potent, pan-genotypic, non-nucleoside, non-structural protein 5B palm polymerase inhibitor being developed for the treatment of chronic hepatitis C (CHC). A first-in-human, randomized, placebo-controlled, dose escalation study, evaluated the safety and pharmacokinetics of GSK2878175 administered as single and repeat oral doses (once daily for 14 days) to healthy volunteers. A separate proof-of-concept, placebo-controlled, repeat dose (once daily for 2 days) study evaluated the safety, pharmacokinetics, and antiviral activity of GSK2878175 monotherapy in treatment naïve, non-cirrhotic, subjects with HCV genotype 1 [1a and 1b], 2, or 3...
July 10, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28685993/association-of-single-nucleotide-polymorphisms-in-micrornas-with-susceptibility-to-hepatitis-b-virus-infection-and-hbv-related-liver-complications-a-study-in-a-saudi-arabian-population
#17
Ahmed A Al-Qahtani, Mashael R Al-Anazi, Nyla Nazir, Kaiser Wani, Ayman A Abdo, Faisal M Sanai, Mohammed Q Khan, Hamad I Al-Ashgar, Ali Albenmousa, Waleed K Al-Hamoudi, Khalid A Alswat, Mohammed N Al-Ahdal
The aim of this study was to evaluate the association of 10 SNPs in different microRNAs (miRNAs) with susceptibility to hepatitis B virus (HBV) infection, HBV clearance, persistence of chronic HBV infection, and progression to liver cirrhosis and hepatocellular carcinoma (HCC). Patients were categorized into the following groups: inactive HBV carrier, active HBV carrier, HBV-cleared subject, and cirrhosis+HCC. Samples were analyzed for 10 SNPs in microRNAs using either PCR-based genotyping or the TaqMan assay...
July 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28685917/on-the-potential-of-a-short-term-intensive-intervention-to-interrupt-hcv-transmission-in-hiv-positive-men-who-have-sex-with-men-a-mathematical-modelling-study
#18
L Salazar-Vizcaya, R D Kouyos, J Fehr, D Braun, J Estill, E Bernasconi, J Delaloye, M Stöckle, P Schmid, M Rougemont, G Wandeler, H F Günthard, O Keiser, A Rauch
Increasing access to direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection and decelerating the rise in high-risk behaviour over the next decade could curb the HCV epidemic among HIV-positive men who have sex with men (MSM). We investigated if similar outcomes would be achieved by short-term intensive interventions like the Swiss-HCVree-trial. We used a HCV transmission model emulating two 12-months intensive interventions combining risk counselling with (i) universal DAA treatment (pangenotypic intervention) and (ii) DAA treatment for HCV genotypes 1 and 4 (replicating the Swiss-HCVree-trial)...
July 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28685914/rates-of-liver-retransplantation-in-the-united-states-are-declining-in-the-era-of-direct-acting-antiviral-agents
#19
G Cholankeril, E R Yoo, M Hu, C Gadiparthi, M A Khan, R B Perumpail, C A Bonham, A Ahmed
No abstract text is available yet for this article.
July 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28685907/the-gamma-glutamyl-transpeptidase-to-albumin-ratio-predicts-significant-fibrosis-and-cirrhosis-in-chronic-hepatitis-b-patients
#20
Q Li, C Lu, W Li, Y Huang, L Chen
Background/Aim Simple, inexpensive and clinically available noninvasive liver fibrosis tests are highly needed. We aimed to develop a novel noninvasive index for predicting significant fibrosis and cirrhosis in chronic hepatitis B (CHB) patients. Methods Using liver histology as gold standard, we developed a novel index to predict significant fibrosis and cirrhosis in CHB patients and then compared the diagnostic accuracy of the novel index, aspartate transaminase-to-platelet ratio index (APRI), and fibrosis index based on four factors (FIB-4) in a training set (606 patients) and a validation set (216 patients) from the same patient catchment area...
July 7, 2017: Journal of Viral Hepatitis
journal
journal
32017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"